LMR Partners LLP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 118 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
LMR Partners LLP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q1 2023$125,093
+145.3%
83,395
+86.4%
0.00%
+100.0%
Q3 2022$51,000
-28.2%
44,7330.0%0.00%0.0%
Q2 2022$71,000
-58.2%
44,733
-38.0%
0.00%
-75.0%
Q1 2021$170,000
+347.4%
72,194
+80.1%
0.00%
+300.0%
Q3 2020$38,000
-7.3%
40,083
-15.0%
0.00%0.0%
Q2 2020$41,00047,1570.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$52,403,2283.69%
Raffles Associates 1,536,946$2,305,4193.14%
Defender Capital, LLC. 5,136,085$7,704,1282.69%
Prescott General Partners LLC 1,851,851$2,777,7770.22%
DAFNA Capital Management LLC 140,000$210,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$67,5000.05%
CTC Capital Management, LLC 14,100$21,1500.04%
Diametric Capital, LP 50,875$76,3130.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$1,172,6490.03%
One68 Global Capital, LLC 13,377$20,0660.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders